Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Sunshine Biopharma (SBFM) over the last 11 years, with Q3 2025 value amounting to $3.5 million.

  • Sunshine Biopharma's Non-Current Assets fell 1361.5% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 1361.5%. This contributed to the annual value of $4.6 million for FY2024, which is 8698.49% up from last year.
  • As of Q3 2025, Sunshine Biopharma's Non-Current Assets stood at $3.5 million, which was down 1361.5% from $4.1 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Non-Current Assets peaked at $4.7 million during Q1 2025, and registered a low of $1642.0 during Q2 2022.
  • Over the past 5 years, Sunshine Biopharma's median Non-Current Assets value was $2.2 million (recorded in 2023), while the average stood at $2.0 million.
  • In the last 5 years, Sunshine Biopharma's Non-Current Assets tumbled by 8782.08% in 2022 and then skyrocketed by 14066205.85% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Non-Current Assets (Quarter) stood at $7061.0 in 2021, then skyrocketed by 27254.68% to $1.9 million in 2022, then rose by 27.2% to $2.5 million in 2023, then soared by 86.98% to $4.6 million in 2024, then dropped by 23.38% to $3.5 million in 2025.
  • Its Non-Current Assets was $3.5 million in Q3 2025, compared to $4.1 million in Q2 2025 and $4.7 million in Q1 2025.